Furthermore, recent RCTs involving GLP-1 receptor agonists and SGLT2 inhibitors included populations with or at high risk of cardiovascular diseases, who may already be receiving antithrombotic therapy (e.g., ∼60%117), thereby further reducing the absolute risk of VTE. The gene discussed is GLP1R; the disease is cardiovascular disorder.